The possibility of resistant hypertension during the treatment of hypertensive patients

Hypertension Research

Volumn 36, Issue 11, 2013, Pages 924-929

  Nishikawa, Tetsuo ^a   Omura, Masao ^a   Saito, Jun ^a   Matsuzawa, Yoko ^a  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

cardiovascular events; obesity; primary aldosteronism; sleep apnea syndrome; white coat syndrome

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; SODIUM; SPIRONOLACTONE;

ABDOMINAL OBESITY; ADRENALECTOMY; AGING; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CUSHING SYNDROME; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERALDOSTERONISM; HYPERCORTISOLISM; HYPERKALEMIA; HYPERTENSION; INCIDENCE; JAPANESE; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT EDUCATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRESSORECEPTOR; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; PROSPECTIVE STUDY; RENAL ARTERY; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SODIUM RETENTION; SYMPATHETIC FUNCTION; WHITE COAT HYPERTENSION;

BLOOD PRESSURE; HUMANS; HYPERTENSION; INCIDENCE; PREVALENCE; TREATMENT FAILURE;

EID: 84887204394     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.107     Document Type: Review

References (53)

1. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
2. Moreno H Jr, Coca A. Resistant and refractory hypertension: Reflection on pathophy-siology and terminology. Blood Pressure 2012; 21: 209-210.
3. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SMALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.
4. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJfor the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.
5. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel HLIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
6. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
7. Julius S, Kjeldsen SE, Weber M et al. VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. RT.
8. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27: 386-391.
9. Daugherty SL, Powers JD, Magid DJ, Masoudi FA, Margolis KL, O'Connor PJ, Schmittdiel JA, Ho PM. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension 2012; 60: 303-309.
10. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774.
11. Ŕios MT, Domínguez-Sardina M, Ayala DE, Gomara S, Sineiro E, Pousa L, Callejas PA, Fontao MJ, Fernández JR, Hermida RC. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 2013; 30: 207-220.
12. Hermida RC, Ríos MT, Crespo JJ, Moyá A, Domínguez-Sardiña M, Otero A, Sánchez JJ, Mojón A, Fernández JR, Ayala DE. Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension. Chronobiol Int 2013; 30: 192-206.
13. Garćia-García A, García-Ortiz L, Recio-Rodŕiguez JI, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Gómez-Marcos MA. Relationship of 24-h blood pressure variability with vascular structure and function in hypertensive patients. Blood Press Monit 2013; 18: 101-106.
14. Fukui M, Ushigome E, Tanaka M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, Oda Y, Hasegawa G, Nakamura N. Home blood pressure variability on one occasion is a novel factor associated with arterial stiffness in patients with type 2 diabetes. Hypertens Res 2013; 36: 219-225.
15. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N, Takami Y, Takeya Y, Rakugi H. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertens Res 2013; 36: 232-239.
16. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, Armario P, Ruilope LM. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30: 1211-1216.
17. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168: 2340-2346.
18. Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009; 169: 874-880.
19. Shafi S, Sarac E, Tran H. Ambulatory blood pressure monitoring in patients with chronic kidney disease and resistant hypertension. J Clin Hypertens 2012; 14: 611-617.
20. de Souza F, Muxfeldt ES, Salles GF. Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev Cardiovasc Ther 2012; 10: 735-745.
21. Barbato A, Galletti F, Iacone R, Cappuccio FP, Rossi G, Ippolito R, Venezia A, Farinaro E, Strazzullo P. Predictors of resistant hypertension in an unselected sample of an adult male population in Italy. Intern Emerg Med 2012; 7: 343-351.
22. Viera AJ. Resistant hypertension. J Am Board Fam Med 2012; 25: 487-495.
23. Abdel-Kader K, Dohar S, Shah N, Jhamb M, Reis SE, Strollo P, Buysse D, Unruh ML. Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. J Hypertens 2012; 30: 960-966.
24. Shimbo D, Levitan EB, Booth JN 3rd, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens 2013; 31: 370-376.
25. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, Schmieder RE, Engeli S, Finer N. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30: 1047-1055.
26. Holecki M, Duawa J, Chudek J. Resistant hypertension in visceral obesity. Eur J Intern Med 2012; 23: 643-648.
27. Pierce GL, Zhu H, Darracott K, Edet I, Bhagatwala J, Huang Y, Dong Y. Arterial stiffness and pulse-pressure amplification in overweight/obese African-American adolescents: relation with higher systolic and pulse pressure. Am J Hypertens 2013; 26: 20-26.
28. Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension 2012; 60: 653-658.
29. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2012; 26: 502-506.
30. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012; 26: 281-287.
31. Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012; 28: 318-325.
32. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164.
33. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783.
34. Whaley-Connell Adam, Megan S, Johnson S, James R. Special articles aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010; 52: 401-409.
35. Pimenta Eduardo, Calhoun David A, Oparil Suzanne. Obstructive sleep apnea symposium. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis 2009; 51: 371-380.
36. Walia H, Strohl K, Koo B, Seicean A, Seicean S. Are sleep symptoms predictors of resistant hypertension in a population-based sample? Findings from the National Health and Nutritional Examination Survey. J Clin Hypertens 2012; 14: 530-536.
37. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83-85.
38. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.
39. Nishikawa T, Saito J, Omura M. Review article-prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocrine J 2007; 54: 487-495.
40. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism; an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.
41. Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-495.
42. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H, Beuschlein F, Seissler J, Rettig R, Felix SB, Biffar R, Döring A, Meisinger C, Peters A, Wichmann HE, Nauck M, Wallaschofski H, Reincke M. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7-15.
43. Douma Stella, Petidis Konstantinos, Doumas Michael, Papaefthimiou Panagiota, Triantafyllou Areti, Kartali Niki, Papadopoulos Nikolaos, Vogiatzis Konstantinos, Zamboulis Chrysanthos. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926.
44. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-152.
45. Handler J. Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. J Clinic Hypert 2012; 14: 732-734.
46. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25: 514-523.
47. Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res 2013; 36: 185-190.
48. Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens 2012; 30: 967-973.
49. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-876.
50. Grassi G, Mancia G. New therapeutic approaches for resistant hypertension. J Nephrol 2012; 25: 276-281.
51. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, Reddy VY. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012; 5: 758-765.
52. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JSA. randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170.
53. Carey RM. Resistant hypertension. Hypertension 2013; 61: 746-750.